Sign inJoin waitlistJoin the waitlist

Jennifer Effie Amengual

Herbert Irving Associate Professor of Medicine in the Division of Hematology and Oncology · Columbia University Irving Medical Center

Credentials: · · · ·

History

Columbia University Irving Medical Center
Present
CUMC
Present

Research

Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission
Journal of Clinical Oncology · 2017 · 129 citations
HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL
Blood · 2011 · 129 citations
A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma
Blood · 2018 · First of 18 authors · 107 citations

OO
Owen O’Connor
19 papers
AS
Ahmed Sawas
13 papers
JL
Jennifer Lue
13 papers · 7 as a fellow
Barbara Pro
10 papers
ST
Seda Tolu
10 papers · 2 as a fellow
Changchun Deng
9 papers
Enrica Marchi
7 papers
MK
Matko Kalac
7 papers · 7 as a resident
SB
Stefan Barta
7 papers
Govind Bhagat
6 papers
Jonathon Cohen
6 papers
Brian Hill
5 papers

Grants

Columbia University NCI Community Oncology Research Program
National Cancer Institute · UG1
PI · $5.1M · Columbia University Health Sciences
2014–2027
Development of First-in-Class Histone Acetyltransferase (HAT) Activators for Precision Targeting of Epigenetic Derangements in Lymphoma
National Cancer Institute · R01
Contact PI · $2M · Columbia University Health Sciences
2018–2023

Clinical trials

Rituximab for PTLD Prevention in Solid Organ Transplant Recipients With EBV DNAemia
Principal investigator · Not yet recruiting · Phase 1
Jennifer Amengual
2026–2028
Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)
Principal investigator · Recruiting · Phase 2
Jennifer Amengual
2025–2028
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
Principal investigator · Recruiting · Phase 2
SWOG Cancer Research Network
2023–2029
Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment
Principal investigator · Active not recruiting · Phase 1
National Cancer Institute (NCI)
2023–2027